钯-103前列腺近距离放疗联合补充外照射的前瞻性评估:44/20/0试验长期结果
44/20和20/0随机试验评估近距离放疗前不同外照射方案对生化失败的影响,长期随访显示各治疗组间生化失败无显著差异,联合队列中生物等效剂量与生化失败无关,作者认为近距离放疗单药应成为临床局限中危前列腺癌的标准治疗。
要点
- 44/20试验中位随访13.7年,全队列及不利中危亚组生化失败无显著差异。
- 20/0试验中位随访10.4年,全队列及不利中危亚组生化失败无显著差异。
- 联合队列630例中,生物等效剂量与生化失败无关。
核心结论
- 近距离放疗单药应成为临床局限中危前列腺癌(包括不利中危疾病)的标准治疗。
研究设计与样本
- 44/20随机试验纳入临床T1c至T2b、Gleason评分7至9分和/或治疗前前列腺特异性抗原10至20 ng/mL的患者,随机接受44 Gy外照射联合90 Gy钯-103或20 Gy外照射联合115 Gy钯-103。
- 20/0随机试验将患者随机分配至20 Gy外照射组或125 Gy钯-103单药组。
- 联合试验队列共630例可分析患者,采用Fine-Gray多因素分析评估生物等效剂量与生化失败的关系。
主要发现
- 44/20试验247例可分析患者,中位随访13.7年,全队列生化失败无显著差异(sHR 0.99;95%CI 0.43-2.276;P=0.97)。
- 44/20试验不利中危亚组生化失败无显著差异(sHR 0.72;95%CI 0.25-2.08;P=0.55)。
- 20/0试验383例可分析患者,中位随访10.4年,全队列生化失败无显著差异(sHR 0.42;95%CI 0.13-1.80;P=0.15)。
- 20/0试验不利中危亚组生化失败无显著差异(sHR 0.81;95%CI 0.16-4.03;P=0.80)。
- 联合队列630例中,调整雄激素剥夺治疗使用、四层美国国家综合癌症网络分类和治疗年份后,生物等效剂量与生化失败无关(1.00;95%CI 0.98-1.02;P=0.88)。
临床怎么用
- 作者认为近距离放疗单药应成为临床局限中危前列腺癌(包括不利中危疾病)的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 44/20 and 20/0 randomized trials evaluated whether different external beam radiation therapy (EBRT) dosing regimens prior to brachytherapy affected biochemical failure (BF). We report long-term outcomes of both trials and evaluate whether biological equivalent dose (BED) was associated with reduced BF in the combined trial cohort. METHODS AND MATERIALS: Both trials enrolled patients with clinical T1c to T2b, Gleason scores 7 to 9, and/or a pretreatment prostate-specific antigen (PSA) 10 to 20 ng/mL disease. The 44/20 trial randomized patients to 44 Gy EBRT with 90 Gy palladium (Pd)-103 versus 20 Gy EBRT with 115 Gy Pd-103. The subsequent 20/0 trial randomized patients to the 20 Gy arm versus monotherapeutic 125 Gy Pd-103. For each trial, univariate Fine-Gray analysis evaluated whether the treatment arm was associated with BF for the entire cohort and the unfavorable intermediate-risk (UIR) subgroup. For the combined trial cohort, multivariate Fine-Gray analysis evaluated whether BED was associated with BF while adjusting for clinical factors. RESULTS: There were 247 analyzable patients in the 44/20 trial. At a median follow-up of 13.7 years, there were no differences in BF for the entire cohort (subdistribution hazard ratio [sHR] 0.99; 95% CI, 0.43, 2.276; P = .97) or the UIR subgroup (sHR 0.72; 95% CI, 0.25, 2.08; P = .55). There were 383 analyzable patients in the 20/0 trial. At a median follow-up of 10.4 years, there were no differences in BF for the entire cohort (sHR 0.42; 95% CI, 0.13-1.80; P = .15) or the UIR subgroup (sHR 0.81; 95% CI, 0.16-4.03; P = .80). For the combined cohort (630 patients), BED was not associated with BF (1.00; 95% CI, 0.98-1.02; P = .88) on multivariate analyses while adjusting for androgen deprivation therapy utilization, 4-tiered National Comprehensive Cancer Network category, and year of treatment. CONCLUSIONS: Brachytherapy monotherapy should be a standard-of-care treatment for clinically localized, intermediate-risk prostate cancer, including UIR disease.
引用
- King MT, Merrick GS, Galbreath RW, et al. Prospective Evaluation of Supplemental External Beam Radiation Therapy With Palladium-103 Prostate Brachytherapy: Long-Term Results of the 44/20/0 Trials. Pract Radiat Oncol. 2024. PMID: 39447863. doi:10.1016/j.prro.2024.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。